Medical treatment of unresectable hepatocellular carcinoma: Going beyond sorafenib

Area of Science:

• Hepatology
• Oncology
• Molecular Biology

Background:

• Sorafenib has improved outcomes for advanced hepatocellular carcinoma (HCC) but is insufficient for many patients.
• A deeper understanding of HCC carcinogenesis mechanisms is essential for developing next-generation therapies.
• HCC remains a significant challenge, necessitating novel therapeutic strategies beyond current standards of care.

Purpose of the Study:

• To review the current landscape of molecularly targeted agents in HCC treatment development.
• To discuss the efficacy and challenges associated with novel therapeutic pathways targeting HCC.
• To explore future directions in HCC drug development, including biomarker identification and response evaluation.

Main Methods:

• Literature review of preclinical and clinical studies on targeted therapies for HCC.
• Analysis of data on various molecular pathways implicated in HCC development and progression.
• Examination of challenges in evaluating treatment response and identifying predictive biomarkers.

Main Results:

• Several molecular pathways, including EGFR, VEGF, mTOR, and Wnt/β-catenin, are being targeted by new agents.
• Multiple targeted agents are in various stages of clinical development for HCC.
• Challenges remain in drug efficacy, response assessment, and biomarker discovery for personalized treatment.

Conclusions:

• Targeted therapies hold promise for improving HCC treatment, building upon Sorafenib's success.
• Continued research into molecular mechanisms and biomarker identification is critical for advancing HCC therapy.
• Overcoming challenges in drug development and clinical evaluation is key to realizing the full potential of novel HCC treatments.